Poster Session - Day 1

Preparing and Presenting your poster:

• Please make the dimensions of your poster no larger than 4’ high X 6’ long. 
• Pushpins and Velcro will be available.  
• Presenters are requested to stay near their posters during the poster session to field questions and discuss their findings.

                                         POSTER SESSION - DAY 1, October 8, 2024

• Abstract/ Poster #	Name	Title
  1	Zhang, Jason	In cell biochemistry of Ras by AI-generated de novo protein tools
  5	Hu, Gloria	Phenotypic CRISPR genome-wide screening for the discovery of genetic regulators of allele-specific mutant KRAS
  7	Wheeler, Joshua	GenialisTM krasID: Biology-Driven Machine Learning to Personalize KRAS Inhibitor Therapy
  9	Hutchins, Chase	Membrane Dynamics and Druggability of Rheb and RhoA
  11	Liu, Junchen	The Role of Sphingolipids in KRAS Plasma Membrane Localization and Function
  13	Shen, Jana	AI Models to Discover Covalently Druggable Sites Across the Proteome
  15	Vagner, Stephan	The RNA binding activity of the BRAF Kinase
  17	Yun, Sangho	Capturing RAS oligomerization on a membrane
  19	Drosten, Matthias	Inactivation of the repressor Capicua abrogates Kras allelic imbalance in lung adenocarcinoma
  21	Fadlalla, Khalda	A novel RAS/β-catenin inhibitor concurrently targets cancer cells and MDSC to reverse the immunosuppressive tumor microenvironment.
  23	Zhang, Wengang	CDK2 and CDK4: Cell Cycle Functions Evolve Distinct, Catalysis-Competent Conformations, Offering Cryptic Drug Targets in RAS-Driven Cancers
  25	Yang, Yang	Discovery and characterization of AFDN as a non-canonical interactor of KRAS that is displaced by RAS inhibitors
  29	Scheidemantle, Grace	An Optimized High-Throughput Top-Down Proteomic Method to Evaluate RAS-Compound Engagement
  31	Das, Jessica	Impact of IMP2 on the regulation of the KRAS signaling pathway in colorectal cancer
  33	Dexheimer, Thomas	Combinations of novel KRAS inhibitors with targeted agents demonstrated greater than additive activity in a range of patient-derived multi-cell type tumor spheroids
  35	Sun, Xin	JAB-3312, a Potent Allosteric SHP2 Inhibitor that Enhances the Efficacy of KRAS G12C Inhibitor Glecirasib
  39	Rudd, Christopher	The GAP, Rasal1, a regulator of p21ras in T-cells controls multiple aspects of tumor immunity
  41	Pita, Lily	Vertical Inhibition of the Autophagy Pathway Enhances Sensitization to RAS MAPK Pathway Inhibition in Pancreatic Ductal Adenocarcinoma
  43	Huisman, Dianna	Tumor Initiation and Therapy Resistance in Small-Cell Lung Carcinoma
  45	Garcia Borrego, Santiago	Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma
  47	Jigo, Raphael	A small molecule RALGDS inhibitor suppresses lung cancer stem cell development and tumorigenesis
  51	Lightstone, Felice	Machine Learning-Driven Multiscale Simulations for Mapping Protein Conformational Transitions, showcased for RAS-RAF Activation
  57	Fer, Nicole	Development of the isogenic H/N/KRAS-less mouse embryonic cell line panel derived from a size sorted diploid clonal parental line.
  59	Lee, Hyun	Wild-type RAS proteins promote mutant NRAS-driven transformation
  61	Dyba, Marcin	MALDI-TOF mass spectrometry-based assay for pocked-directed disulfide tethering fragment screening.
  63	Gokhale, Praful	Therapeutic vulnerability of inhibiting RAS pathway by RMC-7977, a RAS(ON) multi-selective inhibitor in the ovarian and endometrial patient-derived xenograft models
  65	Diao, Shiqi	The Integrated Stress Response drives LUAD tumor progression and presents a promising therapeutic target for treatment
  67	Stauffer, Lucas	Functional characterization of novel germline LZTR1 variants
  69	Castillo, Jean	Optogenetic Control of RAS: Modulating RAS signaling and RAS Clustering
  71	Lohan, Sandeep	Discovery of bicyclic peptides that engage wild-type and mutant KRAS using mRNA display
  73	Tempkin, Jeremy	Free energy and flexibility analysis of complete autoinhibited human BRAF complex by molecular dynamics simulation
  75	Nayak, Kasturi	Crosstalk between RAS and WNK pathways supports viability in CRC following KRASG12C inhibition
  77	Chang, Wen-Hsuan	Defining a molecular signature for KEAP1-NRF2 mediated resistance to KRAS inhibition in pancreatic cancer
  79	Singh, Kanchan	BBO-8520, a first-in-class, direct, and covalent small molecule inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C, demonstrates robust efficacy and compares favorably to GDP-bound KRASG12C (OFF) only inhibitors in preclinical models
  81	Yohe, Marielle	Echocardiographic strain analysis reveals concentric basilar cardiac hypertrophy in an HrasG12S mouse model for Costello syndrome
  83	Long, Szu-Aun	Evaluating direct KRASQ61H inhibition in pancreatic cancer models
  85	Carey, Leiah	Combinatory Structural Biology of NRAS Q61 Melanomagenic Mutants
  87	Shree, Shweta	Lipid Bilayer-Mediated Assembly of Ras-Raf Complexes: Probing Topology and Binding Affinities
  89	Majumder, Anurima	Cell state modulates the KRASG12C proximal proteome.
  91	Diaz-parga, Pedro	Interaction of RAS proteins alter the dynamics of the receptor-binding domain of RALGDS
  95	Liu, Zhaojin	Targeting Aurora Kinase A for Potentiating Colorectal Cancer to KRASg12c Targeted Therapy
  97	Ge, Xiangyu	RAS Nanoenvironment Regulation by Phosphoinositide 3-kinase (PI3K) Drives Adaptive Resistance to KRAS Inhibition in Pancreatic Ductal Adenocarcinoma
  99	Keeton, Adam	Tumor regression and increased survival in mouse models of pancreatic and lung cancer from ADT-030, a novel dual inhibitor of RAS and β-catenin pathways
  101	Caceres, Rodrigo	Understanding RAS-RAF interactions at the real-time single-molecule level
  103	Deck, Samuel	Structural Insights of KRAS Through Multi-Temperature X-Ray Crystallography
  105	Seale, Tessa	Pan-RAS inhibitor RMC-7977 overcomes oncogenic RAS signaling and exerts antileukemic effects in CMML/AML cells
  107	Feng, Siyu	BBO-10203, a first-in-class breaker of the PI3Kα: RAS interaction, demonstrates in vitro and in vivo efficacy alone or in combination with standard-of-care therapies in solid tumor models.
  109	Chareddy, Yogitha	Synergistic co-targeting of MYC and KRAS in lung cancer by ligand-directed inverted chimeric RNAi molecules
  111	Sianoya, Abraham	In vitro evaluation of small molecule inhibitors for KRASG12D pancreatic ductal adenocarcinoma
  113	Gulay, Kevin Christian	Overcoming Chemotherapy Resistance in Pancreatic Cancer: The Impact of Novel RAS Inhibitors and Tumor Microenvironment Modulation
  115	Sahoo, Snehasudha	Dual Targeting of KRAS G12V with EFTX-G12V and RMC-7977 Results in Deeper and More Durable Tumor Responses
  117	Ching, Yan Ming	Concurrent AXL inhibition enhances the anti-tumor efficacy of KRAS and ERK inhibitors in KRAS-mutant pancreatic cancer
  119	Jackson, Peter	Mass Spectrometric Secreteomics of KRAS-regulated tumor secretion in cell lines and primary human tumors
  121	Burge, Rachel	Differential KRAS-mediated PI3K signaling dynamics in human and murine pancreatic ductal adenocarcinoma
  123	Miller, Mason	A Novel PROTAC RAS Inhibitor
  125	Wu, Jinhua	An Isoform-specific region synergies with the RA domain to magnify Rac1 signaling
  P1	Abuasaker, Baraa	Inhibition Of KRAS Oncogenic Activity By Interfering With New KRAS Interactors
  P3	Baker, Andrew	RAS mutations determine sensitivity to the SHP2 inhibitor TNO155 in models of fusion-negative rhabdomyosarcoma.
  P5	Vasudevan, Harish	A transcriptomic, proteomic, and functional genetic atlas of Ras GAP specificity identifies a NF1-KRAS signaling axis in the peripheral nervous system
  P9	Vaseva, Angelina	RAS-GTP Inhibition Enhances Antitumor Efficacy of the RAF/MEK Clamp Avutometinib in NF1-associated Malignant Peripheral Nerve Sheath Tumors
  P11	Clark, Geoff	Pan-RAS inhibitors for NF1 loss driven Malignant Peripheral Nerve Sheath Tumors
  P7	Yohe, Marielle	Efficacy of direct KRAS(G12C) inhibitors in preclinical models of pediatric cancer